ospexin 1000mg tab.
biochemie-austria - tablet - 1000 mg
ospexin 250mg/5ml susp.
biochemie-austria - powder for oral suspension - 250 mg/5ml
ospexin 125mg/5ml susp.
biochemie-austria - powder for oral suspension - 125 mg/5ml
ospexin 1000mg f.c.tab.
biochemie-austria - coated tablet - 1000 mg
retarpen 1.2 m.i.u. vial
biochemie-austria - injection - 1.2 m.i.u.
gentamicin biochemie amp 80 mg/2ml
مستودع ادوية النابلسي - nabulsi drug store - gentamicin 80 mg/2ml - 80 mg/2ml
xorimax coated tablets 250 mg
novartis corporation (malaysia) sdn. bhd. - cefuroxime axetil -
xorimax coated tablets 500 mg
novartis corporation (malaysia) sdn. bhd. - cefuroxime axetil -
hyrimoz 40mg0.8ml solution for injection in pre-filled pen
novartis corporation (malaysia) sdn. bhd. - adalimumab -
binocrit 1000 iu 0.5 ml
novartis israel ltd - epoetin alfa - solution for injection - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - binocrit® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf):- in adults and children aged 1 to 18 years on haemodialysis and adult patients on peritoneal dialysis .- in adults with renal insufficiency not yet undergoing dialysis for the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients. binocrit® is indicated in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy) for the treatment of anaemia and reduction of transfusion requirements.binocrit® is indicated in adults in a predonation programme to increase the yield of autologous blood.treatment should only be given to patients with moderate anaemia (haemoglobin (hb) concentration range between 10 13 g/dl (6.2 8.1 mmol/l), no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).binocrit® is indicated for non-iron deficient adults prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications to reduce exposure to allogeneic blood transfusions.use should be restricted to patients with moderate anaemia (e.g. hb concentration range between 10 13 g/dl or 6.2 8.1 mmol/l) who do not have an autologous predonation programme available and with an expected blood loss (900 to 1800 ml).